期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 52, 期 13, 页码 1052-1059出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2008.05.054
关键词
fibrinogen; platelet aggregation; clopidogrel; diabetes mellitus; body mass index
Objectives The goal of this study was to identify factors associated with lower platelet inhibition ( PI) with clopidogrel in subjects with cardiovascular disease (CVD). Background A heterogeneous platelet reactivity response to clopidogrel exists, and the clinical or biochemical predictors of suboptimal PI with clopidogrel remain unclear. Methods This study prospectively enrolled subjects with CVD requiring treatment with clopidogrel (75 mg daily for >= 7 days or 600-mg bolus >= 24 h before recruitment). A bedside rapid platelet function assay (VerifyNow, Acccumetrics, San Diego, California) to measure maximal and clopidogrel-mediated platelet reactivity was utilized, and factors associated with lower PI were identified. Results A heterogeneous, normally distributed PI (mean 40.8 +/- 26.2%) response to clopidogrel was observed in 157 subjects (age 67.2 +/- 12.2 years; 59.9% men). Multiple variable analysis of clinical and biochemical factors known to affect platelet reactivity revealed lower PI in patients with an elevated plasma fibrinogen level (>= 375 mg/dl), diabetes mellitus, and increased body mass index (BMI) (>= 25 kg/m(2)). On testing for interaction, elevated fibrinogen level was associated with diabetic status, resulting in lower PI in diabetic patients (23.9 +/- 3.9% vs. 45.1 +/- 4.5%, p < 0.001), but not nondiabetic patients (44.7 +/- 4.4% vs. 46.3 +/- 4.8%, p = 0.244). Increased BMI remained independently associated with lower PI after clopidogrel therapy regardless of diabetic status or fibrinogen level (36.8 +/- 9.0% vs. 49.0 +/- 7.0%, p < 0.001). Conclusions Elevated plasma fibrinogen (>= 375 mg/dl) in the presence of diabetes mellitus and increased BMI (>= 25 kg/m(2)) are associated with lower PI with clopidogrel in patients with CVD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据